AVANIR PHARMACEUTICALS, INC CL A
AVNR
AVNR was delisted on the 12th of January, 2015.
115 hedge funds and large institutions have $711M invested in AVANIR PHARMACEUTICALS, INC CL A in 2014 Q2 according to their latest regulatory filings, with 33 funds opening new positions, 45 increasing their positions, 26 reducing their positions, and 18 closing their positions.
99% more call options, than puts
Call options by funds: $13.9M | Put options by funds: $7.01M
85% more capital invested
Capital invested by funds: $384M → $711M (+$327M)
83% more first-time investments, than exits
New positions opened: 33 | Existing positions closed: 18
73% more repeat investments, than reductions
Existing positions increased: 45 | Existing positions reduced: 26
15% more funds holding
Funds holding: 100 → 115 (+15)
0% more funds holding in top 10
Funds holding in top 10: 1 → 1 (0)
Top Buyers
| Rank | Fund | Capital Flow |
|---|---|---|
| 1 |
BBA
Baker Bros. Advisors
New York
|
+$58.8M |
| 2 |
Millennium Management
New York
|
+$11.5M |
| 3 |
Citadel Advisors
Miami,
Florida
|
+$5.47M |
| 4 |
Fidelity Investments
Boston,
Massachusetts
|
+$5.1M |
| 5 |
AG
Artal Group
Luxembourg
|
+$5.07M |
Top Sellers
| Rank | Fund | Capital Flow |
|---|---|---|
| 1 |
CS
Credit Suisse
Zurich,
Switzerland
|
-$4.06M |
| 2 |
Goldman Sachs
New York
|
-$3.73M |
| 3 |
ISL
Ingalls & Snyder LLC
New York
|
-$3.64M |
| 4 |
Susquehanna International Group
Bala Cynwyd,
Pennsylvania
|
-$2.66M |
| 5 |
BFA
BlackRock Fund Advisors
San Francisco,
California
|
-$2.09M |
| Name | Holding | Trade Value |
Shares Change |
Change in Stake |
|
|---|---|---|---|---|---|
|
N
126
Natixis
Paris,
France
| – | -$65K | -17,700 | Closed |
|
127
Comerica Bank
Dallas,
Texas
| – | -$50K | -13,563 | Closed |
|
|
GC
128
Guggenheim Capital
Chicago,
Illinois
| – | -$49K | -13,395 | Closed |
|
|
RCM
129
Reynolds Capital Management
Las Vegas,
Nevada
| – | -$46K | -12,600 | Closed |
|
|
BBA
130
BLB&B Advisors
Montgomeryville,
Pennsylvania
| – | -$46K | -12,500 | Closed |
|
|
GA
131
Geneva Advisors
Chicago,
Illinois
| – | -$40K | -11,000 | Closed |
|
|
OC
132
Oppenheimer & Co
New York
| – | -$37K | -10,000 | Closed |
|
|
TRCT
133
Tower Research Capital (TRC)
New York
| – | -$12K | -3,287 | Closed |
|
AVNR Hedge Fund Activity: Q2 2014 in Review
115 of the 3,481 institutional investors tracked by Wall St. Rank reported a position in AVANIR PHARMACEUTICALS, INC CL A (AVNR) for Q2 2014, worth a combined $711M — up 85% from $384M a quarter earlier.
Buyers outnumbered sellers: 33 funds opened new AVNR positions and 18 closed out — a net gain of 15 holders — while 45 added to existing stakes and 26 trimmed.
The largest buyer was Baker Bros. Advisors, adding an estimated $58.8M. The largest seller was Credit Suisse, cutting an estimated $4.06M.
- 115 institutional investors held AVANIR PHARMACEUTICALS, INC CL A (AVNR) as of Q2 2014, up from 100 in Q1 2014.
- Funds reported $711M of AVANIR PHARMACEUTICALS, INC CL A stock for Q2 2014, up 85% quarter-over-quarter.
- 33 funds opened new AVANIR PHARMACEUTICALS, INC CL A positions in Q2 2014 and 18 closed out, a net change of +15 holders.
- The largest AVANIR PHARMACEUTICALS, INC CL A buyer in Q2 2014 was Baker Bros. Advisors, an estimated $58.8M added.
- The largest AVANIR PHARMACEUTICALS, INC CL A seller in Q2 2014 was Credit Suisse, an estimated $4.06M sold.
Based on aggregated 13F filings for Q2 2014.